An Investigation of Survival following Ovarian Cancer

Authors

  • Jamil Hasan Karami University of Dhaka
  • Kehui Luo Macquarie University
  • Thomas Fung Macquarie University
  • Jonathan Carter University of Sydney
  • Zongqun Ding University of Sydney

DOI:

https://doi.org/10.18034/mjmbr.v6i1.470

Keywords:

Ovarian cancer, prognostic factor, survival analysis, Cox model, Kaplan-Meier curve

Abstract

Ovarian cancer is one of the most malignant gynaecological cancer for women. Women with ovarian cancer generally have a poor prognosis with short survival. In our study, an exploratory analysis was carried out using the data routinely collected on patients with ovarian cancer, who were diagnosed and treated in a large hospital in Sydney. Survival following the diagnosis of ovarian cancer was examined in relation to several important prognostic factors, including FIGO stage, age, residual disease and histologic type, aiming to evaluate the effect size of each factor and build up a predictive model for survival. The predicted survival provides valuable information for patients and their families, and is particularly important in helping clinician and hospital with the management of each patient with ovarian cancer.

 

Downloads

Download data is not yet available.

Author Biographies

  • Jamil Hasan Karami, University of Dhaka

    Department of Statistics, University of Dhaka, Dhaka 1000, BANGLADESH

  • Kehui Luo, Macquarie University

    Department of Statistics, Macquarie University, Sydney, NSW 2109, AUSTRALIA

  • Thomas Fung, Macquarie University

    Department of Statistics, Macquarie University, Sydney, NSW 2109, AUSTRALIA

    and

    Honorary Associate, University of Sydney, AUSTRALIA

  • Jonathan Carter, University of Sydney

    Lifehouse Gynaecologic Oncology Group, Sydney Cancer Centre, University of Sydney, AUSTRALIA

  • Zongqun Ding, University of Sydney

    Lifehouse Gynaecologic Oncology Group, Sydney Cancer Centre, University of Sydney, AUSTRALIA

References

Barnholtz-Sloan, J. S., Schwartz, A. G., Qureshi, F., Jacques, S., Malone, J., and Munkarah, A. R. (2003), “Ovarian Cancer: Changes in patterns at diagnosis and relative survival over the last three decades”, American Journal of Obstetrics and Gynecology, Vol. 189, pp. 1120-1127.

Bast, R. C. Jr, Feeney, M., Lazarus, H., Nadler, L. M., Colvin, R. B., and Knapp, R. C. (1981), “Reactivity of a monoclonal antibody with human ovarian carcinoma”, J Clin Invest, Vol. 68, pp. 1331-1337.

Burton, A., Altman, D. G., Royston, P., and Holder, R. L. (2006), “The Design of Simulation Studies in Medical Statistics”, Statistics in Medicine, Vol. 25, pp. 4279-4292.

Chan, J. K., Cheung, M. K., Husain, A., Teng, N. N., West, D., Whittemore, A. S., Berek, J. S., and Osann, K. (2006), “Patterns and progress in ovarian cancer over 14 years”, Obstetrics & Gynecology, Vol. 108, pp. 521-528.

Colombo, P. E., Mourregot, A., Fabbro, M., Gutowski, M., Saint-Aubert, B., Quenet, F., Gourgou, S., and Rouanet, P. (2009), “Aggressive surgical strategies in advanced ovarian cancer: A monocentric study of 203 stage IIIC and IV patients”, The Journal of Cancer Surgery, Vol. 35, pp. 135-143.

Cox, D.R. (1972), “Regression Models and Life-Tables”, Journal of the Royal Statistical Society, Vol. 34, pp. 187-220.

Eisenhauer, E. A., Gore, M., and Neijt, J. P. (1999), “Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner?”, Annals of Oncology, Vol. 10, pp. 9-15.

Felder, M., Kapur, A., Gonzalez-Bosquet, J., Horibata, S., Heintz, J., Albrecht, R., Fass, L., Kaur, J., Hu, K., Shojaei, H., Whelan, R. J., and Patankar, M. S. (2014), “MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress”, Molecular Cancer, Vol. 13, pp. 129.

Kaplan, E.L. and Meier, P. (1958), “Nonparametric estimation from incomplete observations”, Journal of the American Statistical Association, Vol 53, pp. 457-481.

Kotsopoulos, J., Moody, J. R. K., Fan, I., Rosen, B., Risch, H. A., McLaughlin, J. R., Sun, P., and Narod, S. A. (2012), “Height, weight, BMI and ovarian cancer survival”, Gynecologic Oncology, Vol. 127, pp. 83-87.

Markmann, S., Gerber, B., and Bries, V. (2007), “Prognostic Value of Ca 125 Levels during Primary Therapy. Anticancer Research”, Vol. 27, pp. 1837-1840.

Obermair, A., Tang, A., Kondalsamy-Chennakesavan, S., Ngan, H., Zusterzeel, P., Quinn, M., Carter, J., Leung, Y., and Janda, M. (2013), “Nomogram to predict the probability of relapse in patients diagnosed with borderline ovarian tumors”, International Journal of Gynecological Cancer, Vol. 23, pp. 264-267.

Polterauer, S., Vergote, I., Concin, N., Braicu, I., Chekerov, R., Mahner, S., Woelber, L., Cadron, I., Van Gorp, T., Zeillinger, R., Castillo-Tong, D. C., and Sehouli, J. (2012), “Prognostic Value of Residual Tumor Size in Patients with Epithelial Ovarian Cancer FIGO Stages IIA--IV: Analysis of the OVCAD Data”, International Journal of Gynecological Cancer, Vol. 22, pp. 380-385.

Rochon, J. and du Bois, A. (2011), “Clinical research in epithelial ovarian cancer and patients’ outcome”, Annals of Oncology, Vol. 22, No. 7, pp. 16-19.

Roett, M.A., and Evans, P. (2009), “Ovarian Cancer: An Overview”, American Family Physician, Vol 80, pp. 609-616.

Schmidt, C. (2011), “CA-125: A Biomarker put to the test”, Journal of the National Cancer Institute, Vol. 103, pp. 1290-1291.

Seiden, M. V. (2001), “Ovarian Cancer”, The Oncologist, Vol. 6, pp. 327-332.

Tingulstad, S., Skjeldestad, F.E., Halvorsen, T.B., and Hagen, B. (2003), “Survival and Prognostic Factors in Patients with Ovarian Cancer”, Obstetrics & Gynecology, Vol. 101, pp. 885-891.

Winter, W.E., Maxwell, G.L., Tian, C., Sundborg, M.J., Rose, G.S., Rose, P.G., Rubin, S.C., Muggia, F., McGuire, W.P. (2008), “Tumour residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: A gynecologic oncology group study”, Journal of Clinical Oncology, Vol. 26, pp. 83-89.

-- 0 --

Downloads

Published

2019-06-30

Issue

Vol. 6 No. 1 (2019): January - June Issue

Section

Peer-reviewed Article

License

The CC BY-NC 4.0 license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge & be non-commercial, they don’t have to license their derivative works on the same terms.
|| View License Deed ||
|| View Legal Code ||
 
Publishing paper with the "Malaysian Journal of Medical and Biological Research" means that the author or authors retain the copyright in the paper.
This journal is granted an exclusive noncommercial reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis, etc, so long as the use is not directed at a commercial advantage or toward private monetary gain.
The author(s) can reuse the figures and tables and other information contained in their paper published by Malaysian Journal of Medical and Biological Research in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at a private monetary gain or commercial advantage.

How to Cite

Karami, J. H. ., Luo, K. ., Fung, T. ., Carter, J. ., & Ding, Z. . (2019). An Investigation of Survival following Ovarian Cancer. Malaysian Journal of Medical and Biological Research, 6(1), 51-58. https://doi.org/10.18034/mjmbr.v6i1.470